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Introduction: Approximately 14% of Australian
women smoke during pregnancy. Although the risk of
adverse outcomes is reduced by smoking cessation,
less than 35% of Australian women quit smoking
spontaneously during pregnancy. Evidence for the
efficacy of bupropion, varenicline or nicotine
replacement therapy as smoking cessation aids in the
non-pregnant population suggest that pharmacotherapy
for smoking cessation is worth exploring in women of
childbearing age. Currently, little is known about the
utilisation, effectiveness and safety of
pharmacotherapies for smoking cessation during
pregnancy; neither the extent to which they are used
prior to pregnancy nor whether their use has changed
in response to related policy reforms. The Smoking
MUMS (Maternal Use of Medications and Safety) Study
will explore these issues using linked person-level data
for a population-based cohort of Australian mothers.
Methods and analysis: The cohort will be
assembled by linking administrative health records for
all women who gave birth in New South Wales or
Western Australia since 2003 and their children,
including records relating to childbirth, use of
pharmaceuticals, hospital admissions, emergency
department presentations and deaths. These
longitudinal linked data will be used to identify
utilisation of smoking cessation pharmacotherapies
during and between pregnancies and to explore the
associated smoking cessation rates and maternal and
child health outcomes. Subgroup and temporal
analyses will identify potential differences between
population groups including indigenous mothers and
social security recipients and track changes associated
with policy reforms that have made alternative smoking
cessation pharmacotherapies available.
Ethics and dissemination: Ethical approval has
been obtained for this study. To enhance the
translation of the project’s findings into policy and
practice, policy and clinical stakeholders will be
engaged through a reference group and a policy forum
will be held. Outputs from the project will include
scientific papers and summary reports designed for
policy audiences.
INTRODUCTION
Maternal smoking during pregnancy is a
leading cause of adverse pregnancy out-
comes, with increased risk of placental
abruption, preterm delivery, low birth weight
and perinatal mortality.1–3 The harms of
maternal smoking extend well beyond the
perinatal period to increase the risk of
adverse outcomes to the child in early life,
including sudden infant death syndrome,4
asthma,5 lower respiratory illnesses and hos-
pitalisation.6 The prevalence of smoking
during pregnancy is declining,7 but it is still
common, with data from 2010 indicating that
13.5% of pregnant Australian women
smoked.8 Although the risk of adverse out-
comes can be significantly reduced by quit-
ting,2 9–10 only 4–34% of Australian women
who smoke early in pregnancy stop later in
their pregnancy.11 Of further concern is the
observation that the lowest cessation rates are
among the heaviest smokers,12 13 who are at
the greatest risk of harm.1 6 The risk of harm
related to smoking in pregnancy is increased
in some subpopulations of Australian women
and their children. In particular, indigenous
women and women of low socioeconomic
ARTICLE SUMMARY
Strengths and limitations of this study
▪ In a context where experimental studies are not
feasible, this population-based cohort study will
enable exploration of longitudinal relationships
while minimising the risk of selection bias.
▪ There are advantages and disadvantages asso-
ciated with the use of administrative data; while
biases associated with recall and socially desir-
able reporting are minimised, the identification of
smoking and medication exposure is likely to be
incomplete.
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status (SES) are at least three-times more likely than
other mothers to smoke during pregnancy, more likely
to be heavy smokers and significantly less likely to quit
smoking during their pregnancy.14
Strategies that effectively aid quitting smoking during
pregnancy, especially among women at elevated risk, are
urgently needed. Behavioural smoking cessation inter-
ventions in pregnant women produce modest outcomes,
reducing the prevalence of smoking during pregnancy
by only 6%.10 Behavioural interventions achieve similarly
low cessation in non-pregnant smokers, but when com-
bined with pharmacotherapy, cessation rates increase
1.5-fold to 3-fold,15 with the greatest relative benefit
achieved in the heaviest smokers.16 Although there has
been some uptake of pharmacotherapies among preg-
nant smokers, it is unclear whether this is advisable, as
the benefits and risks of using these medications during
pregnancy have not been adequately assessed.
Smoking cessation pharmacotherapies
Three medications are licensed for use as smoking cessa-
tion aids in Australia: nicotine replacement therapy
(NRT), bupropion and varenicline. NRT aims to reduce
withdrawal symptoms by providing some of the nicotine
that would otherwise be obtained from cigarettes, while
limiting exposure to harmful substances in tobacco. It is
available in the form of transdermal patches, inhalers,
lozenges, sublingual tablets and gum. Bupropion is a
non-nicotine drug and although its exact mechanism of
action is unclear, it was observed to alleviate nicotine
withdrawal symptoms while being used as an antidepres-
sant.17 Varenicline is a partial agonist of the nicotine
receptor, stimulating the dopamine reward pathway to a
lesser extent than nicotine, but preventing nicotine itself
from binding.17 Current guidance recommends against
the provision of varenicline during pregnancy and sug-
gests the use of bupropion or NRT only when the
expected benefits outweigh the potential risks.18
Although access to NRT initially required a prescrip-
tion in Australia, it has been available over the counter
(OTC) since 1997. Since 1 January 2009, NRT patches
have been subsidised through the Pharmaceutical
Benefits Scheme (PBS) for indigenous patients and the
subsidy was extended to all patients on 1 February
2011.19 The cost of a full 12-week course of NRT if
bought OTC is currentlyi $A165.95, while the subsidised
costs are $A108.30 for general beneficiaries and $A17.70
for social security beneficiaries. Bupropion and vareni-
cline are prescription only and they have been PBS
listed for all eligible patients since 1 February 2001 and
1 January 2008, respectively. Subsidies are such that the
maximum out-of-pocket cost for a full course of bupro-
pion or varenicline is $A72.20 for general patients and
$A11.80 for social security patients. Subsidised supply is
restricted to individuals who have indicated they are
ready to cease smoking and have entered or are enter-
ing a comprehensive support and counselling pro-
gramme.20 Bupropion is not PBS-subsidised as an
antidepressant in Australia.
Use of smoking cessation pharmacotherapies during
pregnancy
Smoking cessation pharmacotherapies are currently
being used during pregnancy, despite the uncertainty
surrounding their safety and efficacy. Population-based
record linkage studies of pregnancies in Denmark
between 1996 and 2002 and in Tayside, Scotland in
2007, found that 8%21 and 16%22 of smokers, respect-
ively, used NRT during pregnancy. Among pregnant
smokers enrolled in a randomised controlled trial
(RCT) of telephone counselling for smoking cessation
conducted in Massachusetts between 2001 and 2004, 3%
reported using bupropion during their pregnancy and
7% used NRT.23 Furthermore, surveys of obstetric provi-
ders in the USA and the UK have found 26–44% of
obstetric providers prescribe these pharmacotherapies to
patients who smoke.24–26 As yet, there are no published
data on the use of varenicline during pregnancy,
however, given that it is the most effective of the three
pharmacotherapies in the non-pregnant population,27
some use during pregnancy is plausible. With the excep-
tion of estimates produced through the power calcula-
tions for this study, the extent to which these
medications are used by Australian women during preg-
nancy is unknown. Although existing utilisation data are
from Western countries with similar guidelines to
Australia,28 the out-of-pocket costs for prescription medi-
cines in Australia are slightly higher than in Denmark,
almost twice those in Scotland, but only a fraction of
those in the USA.29 30 Given that prescription medicine
utilisation is highly sensitive to out-of-pocket costs,31 util-
isation rates in Australia are likely to differ from those
documented internationally. Furthermore, the policy
reforms in Australia over the last decade that has made
alternative smoking cessation pharmacotherapies avail-
able and reduced their out-of-pocket costs, are likely to
have resulted in increased utilisation.
Benefits and risks of smoking cessation
pharmacotherapies during pregnancy
Although RCTs provide the best evidence regarding the
benefits and risks of an intervention, RCTs of bupropion
and varenicline in pregnancy are not ethically accept-
able given their unknown safety during pregnancy.
Consequently, robust observational studies offer the only
feasible method for obtaining evidence regarding the
effects of these agents in pregnancy. As yet, no such
studies of varenicline has been reported, however, data
relating to bupropion use in pregnancy exist, much of it
in the context of treating depression.32–34 Although the
lack of a control group meant that no definitive
iAt the time of writing, the purchasing power of $A1 was 0.74 British
pounds (GB£) and US$0.66; http://stats.oecd.org/Index.aspx?
DataSetCode=CPL
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conclusions could be drawn from the bupropion registry
set up by the manufacturer,35 its findings raised concern
about the possibility of an association between bupro-
pion use in pregnancy and cardiovascular malforma-
tions. This prompted the conduct of controlled
observational studies, which found no evidence of
increased congenital abnormalities among women
taking bupropion during pregnancy relative to those
exposed to other antidepressants34 and those not
exposed to any teratogens.33 An increased risk of spon-
taneous abortion33 and infant left outflow heart
defects32 was observed for pregnant bupropion users
relative to women not taking potentially teratogenic sub-
stances, but given that no comparisons were made with
pregnant smokers, these findings provide little insight
into the safety of bupropion relative to smoking during
pregnancy. The only study to include a pregnant smoker
comparison group was a very small (n = 44) matched
controlled study which found a significantly higher ces-
sation rate among women taking bupropion (45% vs
14%, p = 0.047).36 This study did not report the safety of
bupropion.
Although nicotine is toxic, when delivered through
NRT it is not accompanied by the other toxins present
in tobacco smoke. Theoretically, this implies that NRT is
safer than smoking during pregnancy and some experts
sanction its use during pregnancy on this basis.37 There
is currently insufficient evidence to support or refute
this assumption, however, with recent meta-analyses28 of
findings from RCTs showing NRT to be associated with
improvements in five of seven pregnancy and neonatal
outcomes, but not to a statistically significant extent.
Similarly, the pooled estimates of smoking cessation
rates were such that the effectiveness of NRT in preg-
nancy remains unclear and the authors recommend that
further RCTs be conducted. Public awareness of the
uncertainty surrounding NRT use during pregnancy,
however, is proving to be a barrier in obtaining RCT
samples of sufficient size,38 adding further weight to the
utility of observational studies in this area. Data from
observational studies reported thus far have shed some
light on the question of NRT safety during pregnancy,
with a population-based cohort study in Denmark
finding no association between NRT and stillbirth,21 but
an increased risk of congenital malformations in preg-
nant NRT users relative to unmedicated non-smokers.39
The impact of NRT on other pregnancy, neonatal and
early childhood outcomes remains to be examined and
further investigation of the effectiveness of NRT in preg-
nant smokers is required.
Use and effectiveness of smoking cessation
pharmacotherapies prior to pregnancy
While the effectiveness and safety of smoking cessation
pharmacotherapies during pregnancy are largely
unknown, it seems prudent to encourage women who
are unlikely to stop smoking spontaneously during preg-
nancy to complete this form of treatment prior to
conception. Although this is not necessary for all female
smokers of reproductive age, given that up to 35% are
able to quit spontaneously when they become preg-
nant,11 it appears appropriate for women who smoked
throughout a previous pregnancy since two-thirds of
these women smoke during subsequent pregnancies.40
Despite this, the extent to which these therapies are
being used prior to pregnancy by Australian women,
particularly those at increased risk of harm, is currently
unknown, as is the degree to which Federal government
policy changes regarding access to these medications
have had an impact on this population. Moreover, the
suggestion that use of smoking cessation pharmacothera-
pies should be encouraged among women who persist
with smoking throughout pregnancy is based on the
assumption that these pharmacotherapies are as effect-
ive in these women as in the general population, which
has not been confirmed. Indeed, the distinctive profile
of women who continue to smoke throughout preg-
nancy, in terms of education, income and heaviness of
smoking,12–14 suggest that estimates of effectiveness from
general population samples may not be applicable to
pregnant women who smoke.
Using comprehensive linked person-level data, the
Smoking MUMS (Maternal Use of Medications and
Safety) Study will explore the utilisation and effective-
ness of bupropion, varenicline and NRT prior to and
during pregnancy, as well as health outcomes for
mothers and babies when these medications are used
during pregnancy. Our specific objectives are as follows:
1. To measure utilisation of publicly subsidised pharma-
cotherapies for smoking cessation during pregnancy
and interpregnancy periods;
2. To measure the extent to which the use of smoking
cessation pharmacotherapies during pregnancy and
interpregnancy periods has changed with the intro-
duction of national policies regarding subsidies for
these medications;
3. To investigate potential differences between subpopu-
lations in the utilisation of medications during preg-
nancy and the interpregnancy period and the impact
of relevant policy changes on utilisation during these
periods;
4. To measure smoking cessation rates associated with
the use of smoking cessation pharmacotherapies
during pregnancy and interpregnancy periods;
5. To investigate maternal and child health outcomes
associated with the use of smoking cessation pharma-
cotherapies during pregnancy.
METHODS AND ANALYSIS
Study design and population
This is a population-based cohort study, comprising all
women who gave birth in New South Wales (NSW) or
Western Australia (WA) since 2003. Records from the
NSW and WA statutory midwifery data collections will be
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linked to PBS data and a range of state-based administra-
tive health data collections.
Data sources
The cohort will be constructed from records in the NSW
Perinatal Data Collection (PDC) and the WA Midwives
Notification Scheme (MNS), which include records for
all live births and stillbirths of at least 20 weeks gestation
or at least 400 g birth weight in NSW and WA.
Information on maternal characteristics, pregnancy com-
plications and labour, delivery and neonatal outcomes
are recorded by the attending midwife or doctor.
Initially the cohort will include pregnancies relating to
births in the period 1 January 2003 to 31 December
2010 (approximately 1 million births) and in later years
of the project the cohort will be expanded to include
more recent births. Pre-2003 midwifery records for
cohort members will also be obtained as they provide
relevant information regarding previous pregnancies.
These data are available from 1994 in NSW and 1980 in
WA.
The PBS data collection includes a record for every
pharmaceutical product for which a subsidy is paid
under this Australian Commonwealth government
scheme. Records contain the item name, anatomical
therapeutic chemical (ATC) code, date of prescribing,
date of supply, the patient’s postcode and their benefi-
ciary status (social security or general). All records of
supply of bupropion, varenicline and NRT to women in
the cohort on or after 1 January 2003 will be obtained
(ATC codes with the prefix N07BA). Although data
regarding bupropion dispensing are available from
2001, personal identifiers for social security beneficiaries
were recorded inconsistently in PBS data prior to 2003,
rendering these early data partially unreliable for
linkage studies.
The NSW Admitted Patients Data Collection (APDC)
and the WA Hospital Morbidity Data Collection
(HMDC) include a record for every public and private
hospital separation in NSW and WA. All available
records belonging to cohort members or their children
will be obtained (from 1 July 2000 in NSW and 1980 in
WA). The information reported includes patient demo-
graphics, diagnoses, procedures and external causes of
injuries coded according to the Australian modification
of the International Statistical Classification of Diseases
and Related Problems, 10th revision (ICD-10-AM)41 for
all APDC records and HMDC records of separations on
or after 1 July 1999. HMDC records relating to separa-
tions between 1 January 1979 and 31 December 1987
are coded according to the ninth revision (ICD-9),
whereas HMDC records between 1 January 1988 and 30
June 1999 are coded according to the Clinical
Modification of the ninth revision (ICD-9-CM).
The NSW Emergency Department Data Collection
(EDDC) and the WA EDDC include a record for every
presentation to all metropolitan and the majority of
regional, emergency departments in NSW and WA.
Recorded information includes patient demographics,
provisional diagnoses and procedures. All available
records for the cohort and their children will be
obtained from 2005 in NSW and 2002 in WA.
The NSW Registry of Births, Deaths and Marriages
(RBDM) Death Registrations and the WA RBDM Death
Registrations include a record for each registered death
in NSW and WA. Information in RBDM data is limited
to date of death, with information on underlying causes
of death and contributing causes of death obtained
from the Australian Bureau of Statistics (ABS) Mortality
Data. Records of all registered deaths among cohort
members and their children will be obtained. RBDM
records up to December 2012 are currently available for
linkage, while ABS Mortality records beyond December
2007 are not yet available.
Data linkage
The Australian Institute of Health and Welfare will
perform linkage of the PBS and midwifery records for
our study. Other records relating to WA residents will be
linked by the WA Data Linkage Branch, while records
relating to NSW residents will be linked by the Centre
for Health Record Linkage. Records are linked using
probabilistic matching of name, date of birth, sex and
address using the ‘best practice protocol’ for preserving
individual privacy.42 Quality assurance data show false
positive and false negative rates of 0.3% and <0.1%,
respectively, for NSW43 and both are estimated to be
0.11% for WA.44
Measurement of smoking
The NSW PDC contains an item indicating whether a
mother smoked during the pregnancy and another item
indicating the number of cigarettes smoked per day
during the second half of the pregnancy. For births
since September 1997, the WA MNS also contains an
item indicating whether a mother smoked during the
pregnancy. For births since January 2010, the WA MNS
contains items indicating the number of cigarettes
smoked per day during the first 20 weeks of pregnancy
and the number smoked per day after the first 20 weeks
of pregnancy. In both the NSW APDC and the WA
HMDC, smoking can be recorded by assigning diagnos-
tic codes related to tobacco use (the ICD-10 AM code
relevant to smoking during pregnancy is Z72.0, which
indicates current use of tobacco during the admission
and the previous 28 days).
Smoker pregnancies will be defined as pregnancies
during which any smoking is reported in the midwifery
record or a smoking diagnosis is present in the hospital
admission record associated with the delivery.
Non-smoker pregnancies will be pregnancies during
which smoking is not reported in the midwifery record
and no smoking diagnosis is present in the hospital
admission record associated with the delivery.
Previous smoker pregnancies will be pregnancies among
women who had at least one record of a previous
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pregnancy in the dataset (births from September 1997
in WA and from January 1994 in NSW), where any
smoking during the immediately preceding pregnancy is
recorded in the midwifery record or a smoking diagnosis
is assigned in the hospital admission record associated
with the delivery. Sensitivity analyses, using NSW data
and post-2009 records from WA, will be performed to
assess an alternative definition, based on smoking during
the second half of the immediately preceding pregnancy.
These categories are not exclusive (previous smoker
pregnancies will include smoker and non-smoker preg-
nancies) and will be used in various combinations to
address specific study objectives.
Measurement of potential confounding factors
Maternal age, parity, gestational age, smoking quantity and
year of delivery will be ascertained directly from the mid-
wifery records.
Maternal medical conditions and adverse outcomes of previ-
ous pregnancies which may confound the relationship
between the use of smoking cessation pharmacothera-
pies and maternal and child health outcomes, for
example asthma, hypertension and diabetes, will be
identified through prebirth emergency department and
hospital admission records, through the supply of rele-
vant medications as recorded in PBS data and through
hospital admission records and midwifery records asso-
ciated with previous births.
Other prescription medication use will be identified
through PBS records.
SES will be ascertained from midwifery and hospital
records and will include individual measures (private
health insurance and concession card holders) and area-
based measures (quintiles of the Socioeconomic Indexes
for Areas, Index of Relative Socioeconomic Advantage
mapped to statistical local area (SLA) of residence45).
Remoteness of residence will be classified according to the
Accessibility Remoteness Indicator of Australia (ARIA)46
applied to SLA of residence ascertained from midwifery
and hospital records.
Indigenous status from hospital admission records will
be used to supplement identification from midwifery
records given that indigenous people are underenumer-
ated in administrative datasets.
Analysis plan for each objective
Objective 1: To measure utilisation of smoking cessation
pharmacotherapies during smoker pregnancies, the
period of pregnancy will be estimated, with the first day
of pregnancy equalling the baby’s date of birth—gesta-
tional age (days) +14 days.47 Instances where the date of
supply of a bupropion, varenicline and NRT falls within
the period of pregnancy will be identified. Utilisation
during interpregnancy periods will be measured among
women with a previous smoker pregnancy, by identifying
instances where the date of supply of a smoking cessa-
tion medication coincides with the period between the
current and previous pregnancy. Utilisation will also be
explored in women with no smoking behaviour
recorded in relation to their current or previous preg-
nancy, to provide information regarding utilisation in
smokers who are not identified as such and women who
take up or resume smoking postpregnancy. Utilisation
counts and rates during each period (ie, pregnancy or
interpregnancy) will be calculated separately for each
smoking cessation pharmacotherapy and for all three
medications together. Trends in utilisation rates for each
period will be assessed using Poisson regression, adjust-
ing for the potential confounders listed above.
Objective 2: Separate interrupted time-series analyses will
be used to identify policy-related changes in the utilisa-
tion of subsidised smoking cessation pharmacotherapies
during pregnancy and interpregnancy periods. The
study period will be divided into segments according to
the date on which each subsidy was introduced. The
magnitude and statistical significance of changes in util-
isation level or trend associated with the subsidy changes
will be measured using Poisson regression models or
Autoregressive Integrated Moving Average models.
Objective 3: To identify potential differentials in the util-
isation of medications during pregnancy and the inter-
pregnancy periods, calculations performed in relation to
objective 1 will be stratified by indigenous status and
SES. Comparisons will be made using χ2 tests and multi-
variate logistic regression to control for the other modi-
fying factors outlined above. To identify potential
differences in the impact of relevant policy changes on
utilisation, indigenous status and SES will be included as
covariates in the models constructed for objective 2.
Objective 4: Cessation of smoking during pregnancy will
be measured among smoker pregnancies by identifying
women who reported not smoking during the second
half of their pregnancy (possible only for NSW and
post-2009 births in WA). Cessation of smoking during
interpregnancy periods will be measured among previ-
ous smoker pregnancies (NSW and WA) using the
mother’s recorded smoking status in the current preg-
nancy. Separate medication-specific cessation rates will
be calculated according to whether a smoking cessation
medication was prescribed during the first half of the
pregnancy or during the interpregnancy period, as
appropriate. Comparisons of cessation rates between
women who were and were not prescribed a smoking
cessation pharmacotherapy during each period of inter-
est will be conducted with χ2 tests and logistic regression
controlling for potential confounders. Analyses regard-
ing the interpregnancy period will be adjusted for the
duration of this period.
Objective 5: Maternal health outcomes will be ascertained
from the midwifery, hospital admissions, emergency
department and death data. Hospitalisations for
seizure-related and mental health conditions during
pregnancy will be examined, as these have been
reported as potential adverse effects of bupropion and
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varenicline, respectively.48 Readmission within 6 weeks
postpartum and all-cause admissions will be examined to
identify potential adverse outcomes that have not been
reported previously. Neonatal outcomes will include low
birth weight (for gestational age), preterm birth
(<37 weeks) and perinatal mortality. To identify potential
adverse outcomes that have not been reported previ-
ously, the infant and child health outcomes initially
explored will be all-cause hospital admissions, emer-
gency department presentations and deaths, followed by
analyses of specific causes should patterns emerge.
Smoker pregnancies will be categorised according to
whether a pharmacotherapy was supplied during the
pregnancy. Comparisons will be made between: (1)
smoker pregnancies during which a pharmacotherapy
was used, (2) smoker pregnancies in which a pharmaco-
therapy was not used and (3) non-smoker pregnancies.
For NSW records and post-2009 WA records, the preg-
nancies during which pharmacotherapy was used will be
further subdivided according to whether smoking
stopped or continued throughout the second half of the
pregnancy. Comparisons will comprise logistic regression
models for binary outcomes and negative binomial
regression modelling for count variables, adjusting for
potential confounders.
In all analyses, we will use techniques such as
Generalised Estimating Equations or multilevel model-
ling to adjust for the clustering of births within the same
women and confounding factors.
Statistical power
Data from national reports49 50 indicate that there were
approximately 135 000 smoker pregnancies in NSW and
WA in 2003–2010 and extrapolation from preliminary
analyses of WA MNS records linked to PBS records
suggest approximately 273 women in NSW and WA were
prescribed bupropion during pregnancy. This sample
will be sufficient to estimate a utilisation rate of 2/1000
pregnancies with a 95% CI of 1.8 to 2.0. Among NSW
women, the minimum detectable rate ratio (RR) for
comparing smoking cessation in bupropion users versus
unmedicated smokers is 2.5 (assuming an unmedicated
cessation rate of 4%). The minimum detectable RRs for
low birth weight, preterm birth and perinatal mortality,
in NSW and WA women, are 1.8, 1.8 and 4.0, respectively
(assuming respective prevalences of 7.3%, 8.2% and
1.1% in unmedicated smokers3). Given the absence of
data on NRT use in pregnant indigenous women,
monthly prescription rates for the general indigenous
population (from the Medicare Australia website51) were
projected and applied, resulting in an estimated 181 pre-
scriptions of NRT among pregnant indigenous women
in 2009–2012. This will allow a utilisation rate of 17/
1000 pregnancies to be estimated with a 95% CI of 14 to
19. In this sample, the minimum detectable RRs for the
above-mentioned outcomes will be 2.8, 2.0, 2.0 and 5.1
for NRT users versus unmedicated smokers. All minimal
detectable RR calculations assumed 80% power, 5%
significance, two-sided tests and an intraclass correlation
for clustering of births within women of 0.46.52 With
respect to varenicline during pregnancy, our project is
exploring completely new territory and consequently
data on which to base power calculations are not
available.
Preliminary analyses of internally linked midwives
records in NSW suggest that, in NSW and WA, there will
be approximately 67 000 previous smoker pregnancies in
2003–2010, 40 000in 2008–2012 and 4500 among indi-
genous women in 2009–2012. Application of general
population prescription rates to estimate interpregnancy
utilisation results in approximately 1600 bupropion pre-
scriptions, giving a rate of 24/1000 (95% CI 23 to 25),
6800 varenicline prescriptions, giving a rate of 167/1000
(95% CI 163 to 170), but only 75 NRT prescriptions for
indigenous women, giving a rate of 17/1000 (95% CI 13
to 21). The minimum detectable RRs for smoking cessa-
tion in the interpregnancy period will be lower than the
during-pregnancy estimates for bupropion, but higher
for NRT among indigenous women.
Ethics and dissemination
To enhance the translation of the project’s findings into
policy and practice, a reference group will be convened,
comprising policy stakeholders and organisations
involved in indigenous and non-indigenous antenatal
care. During the final stages of the project, we will also
hold a policy forum to promote academic, professional
and public debate on policy and practice issues arising
from the project. Outputs from the project will include
scientific papers, summary reports in formats designed
for policy audiences and presentations given at confer-
ences, collaborator meetings and reference group
meetings.
DISCUSSION
The Smoking MUMS Study will provide evidence regard-
ing current policy-relevant and practice-relevant issues.
The findings regarding the effectiveness and safety of
smoking cessation pharmacotherapies during pregnancy
have the potential to inform guidelines relating to the
prescription of these agents during pregnancy, as well as
to guide policy decisions regarding the extent to which
their use should be encouraged and supported, particu-
larly for indigenous and other high-risk mothers. Our
investigation of how changing subsidies for these medi-
cations has driven changes in their use is important
both in terms of evaluating current policies and in
shaping future policy initiatives that aim to influence the
uptake of smoking cessation pharmacotherapies, in
pregnancy and more generally.
An additional benefit of this project is that once the
linkage keys for the study population are established,
there is potential to use this infrastructure (pending
appropriate ethics approval) to examine the utilisation
and safety of other medications during pregnancy,
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simply by obtaining linked PBS records relating to add-
itional medications. Indeed, we plan to conduct a pro-
gramme of research based on this resource, known as
the MUMS Study. This study has the potential to contrib-
ute greatly to knowledge of the safety of medications
during pregnancy, which is currently lacking for many
licensed pharmaceuticals as pregnant women are com-
monly excluded from participating in clinical trials.
Limitations
Although the use of population-based data collections
for research presents various advantages, including large
sample sizes and therefore greater statistical power to
detect rare outcomes, the avoidance of biases associated
with recall or social desirability and the prevention of
selection bias associated with the collection of individual
patient consent and voluntary participation, there are
also limitations.
The first of these relates to the incomplete ascertain-
ment of medication exposure in the PBS data. OTC sales
of NRT do not result in PBS records and will therefore not
be captured in our study. Similarly, use of subsidised
smoking cessation pharmacotherapies may also be under-
ascertained among indigenous women in remote areas
because subsidised supply of medications to indigenous
people in these areas does not always result in an individ-
ual patient-level PBS record. Special arrangements exist
for the supply of pharmaceutical benefits to clients of eli-
gible remote area Aboriginal Health Services, whereby
prescription medications are provided free of charge
without the need for a prescription.53 In addition to
leading to conservative utilisation rates, this underascer-
tainment means the unmedicated smoker pregnancy
group will potentially include some pregnancies in which
NRT, bupropion or varenicline was in fact used. This
would result in a bias of the risk estimates towards the null,
that is, the potential benefits and harms of smoking cessa-
tion pharmacotherapy use will be underestimated.
The second major limitation arises from the reliance on
midwifery and hospital admission data to identify smokers.
It has been shown that smokers are underenumerated in
these data collections, although the rate of false identifica-
tion of smokers is less than 1%.54 55 This underdetection
of smokers will bias comparisons with non-smokers
towards the null, but it is not expected to influence com-
parisons between medicated and unmedicated smokers.
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